Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.87 NOK | -1.02% | +0.41% | -4.13% |
02-15 | Axactor ASA Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 | CI |
02-15 | Axactor ASA Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's high margin levels account for strong profits.
- The equity is one of the most attractive in the market with regard to earnings multiple-based valuation.
- The company appears to be poorly valued given its net asset value.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- With an enterprise value anticipated at 8.75 times the sales for the current fiscal year, the company turns out to be overvalued.
- Revenue estimates are regularly revised downwards for the current and coming years.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Corporate Financial Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-4.13% | 135M | B- | ||
+25.58% | 18.5B | C | ||
+35.11% | 17.48B | B- | ||
+8.58% | 9.59B | B+ | ||
-10.88% | 8.49B | A | ||
+5.52% | 6.36B | B- | ||
+74.76% | 5.84B | - | - | |
+1.64% | 5.06B | B- | ||
+62.35% | 4.45B | - | C | |
-3.57% | 4.2B | - | D+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- AXA Stock
- Ratings Axactor ASA